167 related articles for article (PubMed ID: 11996467)
1. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
5. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
6. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
7. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
9. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
[TBL] [Abstract][Full Text] [Related]
10. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
16. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
[TBL] [Abstract][Full Text] [Related]
18. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
19. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2001 Dec; 23(6):650-7. PubMed ID: 11802099
[TBL] [Abstract][Full Text] [Related]
20. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients.
Sørensen BT; Strömgren A; Jakobsen P; Jakobsen A
Cancer Chemother Pharmacol; 1991; 28(5):397-401. PubMed ID: 1914085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
